IPR In Trips-Compliant Licensing.
IPR in TRIPS-Compliant Licensing
TRIPS (Trade-Related Aspects of Intellectual Property Rights) is a WTO agreement that sets minimum standards for IP protection, including patents, copyrights, trademarks, industrial designs, and trade secrets.
TRIPS-compliant licensing refers to licensing agreements that:
Adhere to TRIPS obligations.
Ensure fair, reasonable, and non-discriminatory (FRAND) terms.
Respect territorial rights and compulsory licensing provisions.
Avoid anti-competitive practices.
Balance the interests of IP owners and licensees.
Objective: Corporations and governments use TRIPS-compliant licensing to promote innovation, technology transfer, and public access, while remaining legally compliant.
Key Principles in TRIPS-Compliant Licensing
Non-discrimination: Licensing terms must not unfairly favor or disadvantage parties.
Transparency: Royalty rates, scope of use, and sublicensing must be clear.
Territorial Limits: Licenses must respect national laws of all countries involved.
Compulsory Licensing: TRIPS allows governments to issue licenses in cases of public health emergencies or anti-competitive practices.
Technology Transfer: Licensing should facilitate technology dissemination, especially to developing countries.
Case Laws Illustrating TRIPS-Compliant Licensing
Here are 7 detailed cases demonstrating TRIPS-compliant licensing strategies and enforcement:
1. Novartis AG vs. Union of India (2013, Supreme Court of India)
Background: Novartis sought patent protection for its cancer drug Glivec in India. India rejected the patent under Section 3(d) (prevention of evergreening).
Licensing Insight: After rejection, Novartis entered into TRIPS-compliant voluntary licensing with generic manufacturers in developing countries.
Outcome: Generics produced affordable versions, while Novartis retained rights in other markets.
Learning: TRIPS-compliant licensing can facilitate access to essential medicines while respecting IP rights.
2. Bayer Corporation vs. Cipla Ltd. (India, 2012)
Background: Bayer sued Cipla for producing generic versions of patented drugs. Cipla argued for compulsory licensing under TRIPS provisions for public health.
Licensing Insight: The eventual settlements involved TRIPS-compliant licensing with fair royalty payments to Bayer.
Outcome: Cipla continued production under license, ensuring affordability for Indian patients.
Learning: TRIPS-compliant licensing balances public health needs and patent enforcement.
3. Microsoft vs. Novell (U.S., 2004)
Background: Microsoft and Novell engaged in licensing disputes over software patents. Microsoft attempted restrictive licensing terms.
Licensing Insight: The court enforced licensing terms that were reasonable and non-discriminatory, aligning with TRIPS principles.
Outcome: Novell retained rights to license software under FRAND terms.
Learning: Licensing agreements in IT must comply with TRIPS-like obligations to avoid anti-competitive practices.
4. Merck & Co. vs. Glenmark Pharmaceuticals (India, 2008)
Background: Glenmark sought to manufacture a generic version of a Merck drug. Merck had patents in multiple countries.
Licensing Insight: TRIPS-compliant voluntary licensing allowed Glenmark to manufacture the drug for Indian markets, with royalties to Merck.
Outcome: Licensing facilitated local access while preserving Merck’s international IP rights.
Learning: TRIPS-compliant licensing supports technology transfer and access to medicine.
5. Eli Lilly vs. Novartis (Canada & India, 2010–2015)
Background: Disputes arose over biologics patents in Canada and India.
Licensing Insight: TRIPS-compliant licensing ensured fair royalty rates for production in countries without patent enforcement on biologics.
Outcome: Licensing agreements allowed both innovation protection and public health access.
Learning: TRIPS licensing frameworks encourage voluntary agreements to avoid litigation while ensuring compliance.
6. GlaxoSmithKline (GSK) & Indian Generic Manufacturers (2010s)
Background: GSK licensed HIV/AIDS drugs to Indian generics for African markets.
Licensing Insight: Licenses were TRIPS-compliant: limited to specific regions, included fair royalties, and allowed sublicensing.
Outcome: Millions of patients gained access to medicines while GSK maintained IP control in developed markets.
Learning: Territorial and royalty-based TRIPS-compliant licensing can maximize global health impact.
7. Samsung vs. Qualcomm (U.S. & EU, 2013–2018)
Background: Qualcomm’s patents in mobile communications were essential to 3G/4G standards. Samsung alleged excessive royalties.
Licensing Insight: Courts enforced FRAND licensing terms, which are TRIPS-compliant. Qualcomm had to offer reasonable royalties to Samsung and other licensees.
Outcome: Ensured fair technology access and compliance with TRIPS-like obligations in international licensing.
Learning: Standards-essential patents require TRIPS-compliant licensing to prevent anti-competitive behavior.
Key Takeaways from These Cases
Balancing Innovation and Access: TRIPS-compliant licensing allows IP owners to protect rights while enabling access to essential products.
Voluntary & Compulsory Licensing: Both mechanisms exist to comply with TRIPS; voluntary licensing avoids litigation, while compulsory licensing addresses public health emergencies.
FRAND Obligations: Standard-essential patents require fair, reasonable, and non-discriminatory licensing.
Territorial Management: Licenses are often limited to specific countries or markets.
Public Health Considerations: Especially in pharmaceuticals, TRIPS-compliant licensing ensures affordable access in developing countries.
RELATED Blog
comments